Outcome of the Board the quarter/half year ended 30/09/2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.3 pts more than Nifty Microcap 250 and 4.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Brawn Biotech's board, at its meeting on 14 November 2025, approved the unaudited financial results for the quarter and half year ended 30 September 2025. Total revenue for H1 FY26 came in at approximately Rs. 1,087 lacs versus around Rs. 736 lacs in H1 FY25, a year-over-year jump of roughly 48%. The company has swung from a loss of about Rs. 87 lacs in H1 FY25 to a small profit in H1 FY26, with EPS moving back into positive territory. The balance sheet also strengthened: total equity rose to Rs. 370 lacs and non-current liabilities were nearly wiped out (from Rs. 780 lacs to nil). Statutory auditor Rajiv Udai & Associates issued an unqualified limited review report with no qualifications or emphasis of matter.
Broadly positive for shareholders - strong revenue growth, a clear swing from loss to profit, and a leaner balance sheet signal improving business momentum. However, absolute profits remain modest relative to revenue, so investors should watch whether the recovery sustains in the coming quarters.